Recommendation of final dividend of INR Rs. 8/- per equity share for FY 2025-26
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Reddys Laboratories Board has recommended a final dividend of INR 8 per equity share (face value Re. 1 each) for FY 2025-26, subject to shareholder approval at the 42nd AGM on July 23, 2026. The record date for determining eligible shareholders is July 10, 2026. For context, FY26 profit attributable to equity holders declined 24% YoY to Rs 42.85 billion due to lower Lenalidomide sales, one-time Shelf Stock Adjustment of Rs 4.53 billion, impairment charges, and VAT provisions. However, full year revenues grew 3.2% YoY to Rs 335.9 billion, driven by emerging markets (+23%), India (+16%), and Europe (+55% YoY, or +14% excluding NRT acquisition).
The dividend signals management confidence despite a challenging year with profit declining 24%. The Rs 8 per share dividend represents an 800% payout ratio, which is significant. Shareholders should expect the dividend after July 23, 2026 upon AGM approval. The company maintains a strong balance sheet with net cash surplus of Rs 32.7 billion.